Cite
MLA Citation
M Soubrier et al.. “AB0696 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in auvergne (france).” Annals of the rheumatic diseases, vol. 76, n.d., p. 1297. http://access.bl.uk/ark:/81055/vdc_100135164210.0x00005e